RUCHIR SEHRA, MD: DROWZLE: THE FIRST FDA CLEARED MOBILE HST TO ASSESS RISK FOR SDB

It’s believed that 80-85 million Americans suffer from obstructive sleep apnea (OSA) . About 80 percent or 18 to 22 million of those adults need treatment but haven’t sought help.

Through sophisticated algorithms and the advancement of digital and mobile technologies, the ability to detect, diagnose and treat sleep apnea has improved  dramatically. These technological advancements have made it easier and more convenient for providers to direct their patients to take charge of their sleep breathing health.

In July 2019, the US Food and Drug Administration (FDA) cleared its first mobile home sleep test for in-home screening of adults with suspected sleep breathing disorders. Results are used to assist the healthcare professional in determining the need for further diagnosis and evaluation.  Although the technology is not intended as a substitute for a full polysomnogram, it is a stand-alone software medical device, available by prescription.

This webinar will address challenges to OSA identification and treatment, as well as how new technologies can advance solving these issues. Dr. Sehra is an accomplished MedTech executive with extensive experience in early (private), mid (public), and late stage (acquisition) medical device companies. Dr. Sehra currently serves as the CEO and President of Resonea Inc., which was founded in 2016. Prior to starting Resonea, he applied his extensive executive leadership to Kyphon, the largest medical device start-up acquisition at $4.2 Billion. He has held many executive positions with a number of medical device companies in the areas of stroke, spinal disease, heart rhythm disorders, interventional cardiology and neuroradiology.  Prior to being an entrepreneur, Dr. Sehra was Professor of Pediatrics and Medicine at Loma Linda University.   He has authored over 100 scientific papers, over 100 worldwide patents, and given hundreds of scientific presentations worldwide.

Register/Info